This is the authors' abstract. We don't add key points for this paper.
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Baselga et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: